Pan-PPAR agonist lanifibranor improves portal hypertension and hepatic fibrosis in experimental advanced chronic liver disease

This publication has 35 references indexed in Scilit:

• The transcription factor KLF2 mediates hepatic endothelial protection and paracrine endothelial–stellate cell deactivation induced by statins
  Journal of Hepatology, 2013
• PPARα activation improves endothelial dysfunction and reduces fibrosis and portal pressure in cirrhotic rats
  Journal of Hepatology, 2012
• Protection from liver fibrosis by a peroxisome proliferator-activated receptor δ agonist
  Proceedings of the National Academy of Sciences, 2012
• Peroxisome proliferator-activated receptor-γ cross-regulation of signaling events implicated in liver fibrogenesis
  Cellular Signalling, 2012
• PPARs in Liver Diseases and Cancer: Epigenetic Regulation by MicroRNAs
  PPAR Research, 2012
• Structure and physiological functions of the human peroxisome proliferator-activated receptor γ
  Archivum Immunologiae et Therapiae Experimentalis, 2008
• Vascular Deterioration in Cirrhosis
  Journal of Clinical Gastroenterology, 2007
• From molecular action to physiological outputs: Peroxisome proliferator-activated receptors are nuclear receptors at the crossroads of key cellular functions
  Progress in Lipid Research, 2006
• Ligands of peroxisome proliferator-activated receptor γ modulate profibrogenic and proinflammatory actions in hepatic stellate cells
  Gastroenterology, 2000
• Endothelial dysfunction and decreased production of nitric oxide in the intrahepatic microcirculation of cirrhotic rats
  Hepatology, 1998